Hypha Discovery: Experts in Metabolite Synthesis
Supporting pharmaceutical and agrochemical companies globally
Your trusted partner in pharmaceutical and agrochemical R&D
What we do
Hypha Discovery is a specialist CRO supporting pharmaceutical and agrochemical companies worldwide through the production of metabolites and late-stage derivatives of drugs and agrochemicals in discovery and development.
We are experts in the scalable synthesis, purification and identification of drug metabolites and oxidised derivatives of lead compounds, and also possess a wealth of experience in the production, purification and structure elucidation of natural products.
Solutions for metabolite synthesis
Hypha Discovery offer a comprehensive suite of techniques for provision of even the most difficult-to-synthesise metabolite, comprising chemical synthesis, recombinant enzymes such as PolyCYPs, microbial biotransformation, mammalian liver fractions as well as the purification of metabolites from biological matrices. We are also experts in the structure elucidation of metabolites by NMR spectroscopy.
PolyCYPs+ screening kits comprise 18 PolyCYP isoforms together with the addition of other phase 1 enzymes. Human aldehyde oxidase (AOX1) and the main human hepatic flavin-containing monooxygenase (FMO3) are included in the kit, with the other human FMO isoforms, available separately at Hypha.
Inclusion of multiple PolyCYPs isoforms broadens coverage of reactions, and which have been proven to produce human and other mammalian CYP-derived metabolites including multi-step metabolites and metabolites of low turnover drugs.
Simple, Effective, Scalable
Produce CYP, AOX & FMO metabolites
Generate multiple hydroxylated and other oxidised derivatives of lead compounds in parallel
Delivering a first class service to our clients worldwide
We look forward to engaging Hypha in the future because their team is professional, and their services complement our internal synthetic efforts for delivering new molecules.
Hypha Discovery News
Major O-demethylated human metabolites of ivermectin that reduce Anopheles survival were made by Hypha’s microbial biotransformation system.
Our Q2 2023 newsletter focusses on synthesis of acyl glucuronides, hydroxylated metabolites and our latest blogs
Metabolites of the FDA approved anti-fungal drug rezafungin were made by Hypha’s microbial biotransformation system.
Meet us at one of the conferences we’ll be attending this year.
Check out our “Metabolite Tales” blog articles on interesting aspects around drug metabolism and medicinal chemistry.
Access brochures on drug metabolite synthesis, Hypha’s one-stop metabolite shop, the PolyCYPs platform and PolarExplorer.
Stay up to date with the latest news from Hypha Discovery
Sign up for our quarterly newsletters and monthly "Metabolite Tales" blog
Ready to begin? Our scientists are available to talk through your requirements
Hypha Discovery is a UK-based CRO supporting pharmaceutical and agrochemical companies worldwide through the production of metabolites and new derivatives of drugs and agrochemicals in discovery and development.